Navigation Links
Cell Biosciences Strengthens Management Team
Date:7/3/2008

PALO ALTO, Calif., July 3 /PRNewswire/ -- Cell Biosciences, Inc., a provider of ultrasensitive protein detection and characterization systems to life science researchers, today announced three key management team additions.

Jason Novi was named Chief Financial Officer, with responsibility for the finance, manufacturing and administrative functions. Prior to joining Cell Biosciences, Mr. Novi was the Vice President, Finance at Nektar Therapeutics. He served as Director of Finance at Molecular Devices Corporation from 2000 to 2007, where he was responsible for all worldwide accounting, finance and treasury functions, and played a key role in the execution and integration of its corporate development activities.

Robert Gavin was named Vice President, Engineering. Mr. Gavin brings nearly 20 years of experience to the Cell Biosciences development team. Most recently, he served as Director of Engineering at MDS Analytical Technologies (previously Molecular Devices), where he directed multidisciplinary teams of mechanical, electrical, firmware, and systems engineers. Mr. Gavin has a strong record of creating highly-successful laboratory systems, including industry-leading optical plate readers and high throughput screening platforms.

Also announced was the appointment of Wilhelm Lachnit, Ph.D. as Vice President, Research and Development. Dr. Lachnit has two decades of experience in pharma/biotech and life sciences. Most recently, he held both scientific and commercial leadership positions at Molecular Devices, where he played a central role in the development and launch of the IonWorks(TM) product line. Previously, he pioneered the early adoption of automated cell-based assays at Roche and Syntex (acquired by Roche). Dr. Lachnit holds a Ph.D. in Pharmacology-Toxicology from the University of California, Davis.

"I am extremely pleased to announce these additions to the Cell Biosciences leadership team," said Tim Harkness, President and Chief Executive Officer. "These individuals have all been key contributors at successful life science companies. I am confident that they will provide exceptionally strong leadership as we develop our portfolio of ultrasensitive nano-proteomics products."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nano-proteomics. We are developing instrumentation systems to enable the detection and characterization of specific proteins in extremely small biological samples. Our company's lead product, the Firefly 3000, is a capillary-based nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of proteins. Cell Biosciences is located in Palo Alto, CA. http://www.cellbiosciences.com


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):